ClinicalTrials.gg
RecruitingNCT05384691LENNONUpdated Jan 31, 2024

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

A Phase 2 interventional study of Luspatercept Injection in Myelodysplastic Syndromes and Anemia, sponsored by University of Leipzig. Recruiting at 22 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-31.

Sponsored by University of Leipzig · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
213
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing luspatercept in Myelodysplastic Syndromes — 6 open to participants now, 12 under way, 6 of them phase 3. luspatercept · Myelodysplastic Syndromes.

Planned enrollment
6th of 19
213 · median 75
Started
2022
with 1 other
Phase 2
9 of 19
3 open now
Primary completion
2026-07
later than 5 of 11 live
Registered
10th of 19
by date

Among the 19 studies testing luspatercept in Myelodysplastic Syndromes, this one is the 6th largest by planned enrollment, is one of 2 that started in 2022, is one of 9 in phase 2, reaches primary completion later than 5 of the 11 other live ones, and was the 10th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

6 of the 19 studies testing luspatercept in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About luspatercept

luspatercept: first FDA approval 2019 (REBLOZYL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing luspatercept in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

Anemia in patients with very low, low or intermediate risk myelodysplastic syndromes (MDS), that are non-transfusion dependent

Read the detailed description

Patients with very low, low or intermediate risk myelodysplastic syndromes (MDS) presenting with anemia, transfusion independence (NTD) and naive towards ESA treatment

03

Conditions studied

  • Myelodysplastic Syndromes
  • Anemia

Keywords

  • MDS
  • Anemia
  • Ring sideroblast
  • Low risk
  • non-transfusion dependence (NTD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of myelodysplastic syndrome (MDS) according to WHO classification
  • Very low-, low-, or intermediate-risk disease MDS with up to 3.5 according to revised International Prognostic Scoring System (IPSS-R)
  • Less than 5% blasts in bone marrow
  • Peripheral blood white blood cell (WBC) count \< 13,000/μL
  • sEPO levels ≤ 500 mU/mL
  • Non-transfusion dependence (NTD) according to IWG 2018 criteria
  • Symptomatic anemia
  • Age > 18 years
  • Written

Exclusion criteria

Exclusion Criteria:

  • Patient does not accept bone marrow sampling during screening and during treatment
  • Patient does not accept regular peripheral blood sampling for screening and during treatment.
  • Patient does not accept subcutaneous application of LUS every three weeks
  • Prior treatment for anemia associated with MDS (i.e. ESA, luspatercept), except previously treated with G-CSF/granulocyte-macrophage colony-stimulating factor (GM-CSF), both agents must be discontinued at least 4 weeks before registration
  • Secondary MDS, i.e. MDS arising as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases
  • Known anemia due to iron, vitamin B12, or folate deficiencies, or or hereditary hemolytic anemia, or gastrointestinal bleeding.
  • Prior or autologous stem cell transplant
  • Prior history of AML
  • Prior history of , other than MDS, unless the subject is free of the disease (including completion of any active or treatment for prior malignancy) for ≥ 5 years.
  • Major surgery within 8 weeks prior to registration.
  • Uncontrolled hypertension, defined as repeated elevations of systolic blood pressure ≥160 mmHg or of diastolic blood pressure (DBP) ≥ 100 mmHg despite adequate treatment
  • count \< 30,000/μL (30 × 10\^9/L)
  • Estimated or \< 40 mL/min
  • (AST)/serum glutamic oxaloacetic transaminase (SGOT) ≥ 3.0 × (ULN)
  • Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) ≥ 3.0 × ULN
  • Total ≥ 2.0 × ULN
  • (ECOG) performance status > 2
  • Stroke, deep venous thrombosis, pulmonary or arterial embolism within 6 months prior to registration
  • Myocardial infarction, uncontrolled angina, uncontrolled heart failure, or uncontrolled cardiac arrhythmia within 6 months prior to registration.
  • Subjects with a known of ˂ 35%, confirmed by a local echocardiography or multigated acquisition scan (MUGA) performed within 6 months prior to registration, are excluded
  • Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment), known (HIV), known evidence of active infectious , and/or known evidence of active .
  • History of severe allergic or anaphylactic reactions or to recombinant proteins or in the IMP
  • Subject has any significant medical condition, laboratory abnormality, psychiatric illness, or is considered vulnerable by local regulations (e.g., imprisoned or institutionalized) that would prevent the subject from participating in the study.
  • Subject has any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she participates in the study
  • Subject has any condition or concomitant medication that confounds the ability to interpret data from the study.
  • Use of any of the following within five weeks prior to registration are prohibited: Anticancer cytotoxic chemotherapeutic agent or treatment, , except for subjects on a stable or decreasing dose for ≥ 1 week prior to inclusion for medical conditions other than MDS, Iron chelation therapy, except for subjects on a stable or decreasing dose for at least 8 weeks prior to registration, Other RBC hematopoietic growth factors (e.g. interleukin [IL]-3)
  • Pregnant or breastfeeding females
  • Positive pregnancy test in women of .
  • Female subjects of childbearing potential unwilling to use a highly effective method of for the course of the study through 90 days after the last dose of study medication.
  • Male subjects with procreative capacity not willing to use a highly effective method of contraception, starting with the first dose of study therapy through 90 days after the last dose of study therapy.
  • Participation in other interventional trials.
  • Patients under legal supervision or guardianship.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
213 participants (estimated)

Study arms

  • Other
    Luspatercept

    Single-arm design: All patients are treated with 1.75 mg Luspatercept per kg body weight subcutaneously on day 1 of each 21 day cycle for up to 24 weeks and in case of response for up to 1.5 years.

    Drug: Luspatercept Injection

Interventions

  • DrugLuspaterceptStudies of LuspaterceptLuspatercept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All formally included patients will receive 1.75 mg/kg luspatercept administered subcutaneously every three weeks (on day 1 of each 21-day cycle) for a duration of 24 weeks. Responders at the response assessment (according to HI-E) in week 25 will be further treated with 1.75 mg/kg luspatercept until loss of response for an expected maximum of 18 months.

    Also known as: LUS

06

What researchers measure

Primary outcomes

  1. Erythroid response (HI-E)

    To evaluate the proportion of patients who have an erythroid response (HI-E) according to the modified IWG 2018 criteria separately for four different clinical situations (cohorts) distinguished by two factors: Serum erythropoietin (sEPO) level AND Ring sideroblast (RS) status

    Time frame: At the end of cycle 8 (each cycle is 21 days)

Secondary outcomes

  1. HI-E response (erythroid response) duration

    To evaluate HI-E response from the first day of response until loss of response.

    Time frame: From the date of treatment start until date of documented loss of response, assessed up to 18 months.]

  2. Time to HI-E (erythroid response)

    To evaluate the time between start of treatment and first day of response.

    Time frame: From the date of treatment start until first day of response, assessed up to end of cycle 8 (each cycle is 21 days)

  3. Neutrophil (HI-N) responses

    Neutrophil (HI-N) responses according to IWG 2018 criteria

    Time frame: At the end of cycle 8 (each cycle is 21 days)

  4. Platelet (HI-P) responses

    Platelet (HI-P) responses according to IWG 2018 criteria

    Time frame: At the end of cycle 8 (each cycle is 21 days)

  5. Safety of luspatercept (toxicities and adverse events)

    Assessments will include characterization of toxicities; characterization of AEs including type, incidence, severity, seriousness, and relationship to treatment

    Time frame: From the date of treatment start until the end of study, assessed up to 48 months

  6. Impact of treatment assessed by using the validated European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ-C30)

    To assess patient-reported quality of life during luspatercept treatment: 30 questions assessing the quality of life of oncology patients across 10 subscales will be analyzed. All subscales have a score range from 0 to 100 points. Function subscales: a higher score represents a higher quality of life. Symptoms subscales: higher score represents higher level of symptoms/problems, i.e., represents lower quality of life.

    Time frame: From the date of treatment start until the end of study, assessed up to 48 months.

  7. Impact of luspatercept on quality of life by using the validated Quality of Life in Myelodysplasia Scale (QUALMS)

    QoL assessment using the QUALMS questionnaire up to end of treatment: 38-item assessment tool for patients with Myelodysplastic Syndromes (MDS) QUALMS scores ranged from 24 to 99, with higher scores for better outcome

    Time frame: From the date of treatment start until the end of study, assessed up to 48 months

07

Study locations

7 of 22 sites recruiting
  • Praxis für Hämatologie und Onkologie Berlin-Mitte
    Berlin, 10117, Germany
    Not yet recruiting
    • Stephan Fuhrmann, Dr. · Contact
  • Universitätsklinikum Bonn
    Bonn, 53127, Germany
    Recruiting
    • Karin Mayer, Dr. · Contact
  • Carl-Thiem-Klinikum Cottbus gGmbH
    Cottbus, 03048, Germany
    Recruiting
    • Maximilian Desole, Dr. · Contact
  • OncoSearch Institut für klinische Studien GbR
    Erlangen, 91052, Germany
    Not yet recruiting
    • Babette Häcker, Dr. · Contact
  • Universitätsmedizin Greifswald Klinik Innere Medizin C / Hämatologie und Onkologie
    Greifswald, 17475, Germany
    Not yet recruiting
    • Florian Heidel, Prof. Dr. · Contact
  • OncoResearch Lerchenfeld GmbH
    Hamburg, 22081, Germany
    Not yet recruiting
    • Thomas Wolff, Dr. · Contact
  • Klinikum Kassel GmbH Klinik für Hämatologie, Onkologie und Immunologie
    Kassel, 34125, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • InVO Institut für Versorgungsforschung in der Onkologie GbR
    Koblenz, 56068, Germany
    Not yet recruiting
    • Christoph Lutz, PD Dr. · Contact
  • VK&K Studien GbR
    Landshut, 84036, Germany
    Recruiting
    • Florian Kaiser, PD Dr. · Contact
  • Universität Leipzig - Medizinische Fakultät Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
    Leipzig, 04103, Germany
    Recruiting
    • Anne Sophie Kubasch, Dr. · Contact
  • Mannheimer Onkologie Praxis
    Mannheim, 68161, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Mannheim, III Medizinische Klinik - Hämatologie und Internistische Onkologie
    Mannheim, Germany
    Not yet recruiting
    • Daniel Nowak, Prof. · Contact
  • Klinikum Hochsauerland GmbH
    Meschede, 59870, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kliniken Maria Hilf GmbH Klinik für Hämatologie, Onkologie und Gastroenterologie
    Mönchengladbach, 41063, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Gemeinschaftspraxis Häamto-Onkologie
    München, 81241, Germany
    Recruiting
    • Matthias Zingerle, Dr. · Contact
  • Klinikum rechts der Isar der TU München III. Medizinische Klinik - Hämatologie und Onkologie
    München, 81675, Germany
    Recruiting
    • Katharina Götze, Prof. Dr. · Contact
  • Universitätsklinikum Münster, Medizinische Klinik A
    Münster, Germany
    Not yet recruiting
    • Jan-Henrik Mikesch, PD Dr. · Contact
  • Studiengesellschaft Onkologie Rhein/RuhrPraxis für Hämatologie und Onkologie Oberhausen und Düsseldorf
    Oberhausen, 46145, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsmedizin Rostock Klinik III (Hämatologie, Onkologie, Palliativmedizin) Zentrum für Innere Medizin
    Rostock, 18057, Germany
    Not yet recruiting
    • Christoph Wittke, Dr. · Contact
  • Praxis ONKOSAAR Praxis für Hämatologie und Onkologie
    Saarbrücken, 66113, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Klinikum Mutterhaus
    Trier, 54290, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Tübingen Medizinische Klinik II, AML/ALL/MDS
    Tübingen, 72076, Germany
    Recruiting
    • Maximilian Christopeit, PD Dr. · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Jul 2026, 46 months after the start.

Of 227 non-industry phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 116. This study's planned 46 months is below that.

Counting every sponsor, half of 279 studies reached it within 65 months; a quarter within 39 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2022
First posted
May 20, 2022
StartActual
Sep 27, 2022
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2027
Last update
Jan 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05384691
Collaborators
Celgene Corporation
Responsible party
Anne Sophie Kubasch (Coordinating Investigator, University of Leipzig) — Principal investigator
First posted
May 20, 2022
Start date
Sep 27, 2022
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Jan 31, 2024

Study contacts

Anne Sophie Kubasch, Dr.
Contact
annesophie.kubasch@medizin.uni-leipzig.de
+49 341 97-13050
Uwe Platzbecker, Prof. Dr.
Contact
uwe.platzbecker@medizin.uni-leipzig.de
Anne Sophie Kubasch, Dr.
principal investigator · University Leipzig

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luspatercept

Start the discussion